alendronate has been researched along with Hyperparathyroidism, Primary in 15 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hyperparathyroidism, Primary: A condition of abnormally elevated output of PARATHYROID HORMONE due to parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. It is characterized by the combination of HYPERCALCEMIA, phosphaturia, elevated renal 1,25-DIHYDROXYVITAMIN D3 synthesis, and increased BONE RESORPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis." | 9.17 | Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013) |
| "Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)." | 7.77 | Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011) |
| "To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis." | 5.17 | Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism. ( Akbaba, G; Ates Tutuncu, Y; Berker, D; Guler, S; Isik, S; Ozuguz, U, 2013) |
| "Cinacalcet is effective in controlling the biochemical abnormalities in patients with primary hyperparathyroidism (PHPT) but it seems to be less effective on bone mineral density (BMD)." | 3.77 | Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. ( Colao, A; Coppola, A; Di Somma, C; Faggiano, A; Gasperi, M; Lombardi, G; Panico, F; Ramundo, V; Savastano, S; Severino, R; Vuolo, L, 2011) |
| " Cinacalcet and vitamin D may have a small or no increase in overall adverse events." | 2.82 | The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Bakaa, L; Bilezikian, JP; Brandi, ML; Chang, Y; Clarke, B; Couban, RJ; Guyatt, G; Khan, AA; Manja, V; Mannstadt, M; Silverberg, SJ; Sreekanta, A; Tangamornsuksun, W; Tong, K; Wang, Y; Ye, Z; Zhang, M; Zhang, Y, 2022) |
| "Primary hyperparathyroidism is a common endocrine disorder that results in elevated levels of parathyroid hormone and subsequent hypercalcaemia." | 2.53 | Primary hyperparathyroidism and the role of the nurse. ( Walker, J, 2016) |
| "Histopathologic analysis revealed a parathyroid adenoma." | 1.36 | Primary hyperparathyroidism with classic and severe skeletal involvement. ( Paz-Pacheco, E; Sandoval, MA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ye, Z | 1 |
| Silverberg, SJ | 1 |
| Sreekanta, A | 1 |
| Tong, K | 1 |
| Wang, Y | 1 |
| Chang, Y | 1 |
| Zhang, M | 1 |
| Guyatt, G | 1 |
| Tangamornsuksun, W | 1 |
| Zhang, Y | 1 |
| Manja, V | 1 |
| Bakaa, L | 1 |
| Couban, RJ | 1 |
| Brandi, ML | 1 |
| Clarke, B | 1 |
| Khan, AA | 1 |
| Mannstadt, M | 1 |
| Bilezikian, JP | 1 |
| Rajput, S | 1 |
| Dutta, A | 1 |
| Rajender, S | 1 |
| Mithal, A | 1 |
| Chattopadhyay, N | 1 |
| Szymczak, J | 2 |
| Bohdanowicz-Pawlak, A | 2 |
| Akbaba, G | 1 |
| Isik, S | 1 |
| Ates Tutuncu, Y | 1 |
| Ozuguz, U | 1 |
| Berker, D | 1 |
| Guler, S | 1 |
| Minisola, S | 1 |
| Cipriani, C | 1 |
| Piemonte, S | 1 |
| Colangelo, L | 1 |
| Pepe, J | 1 |
| Romagnoli, E | 1 |
| Cesareo, R | 1 |
| Di Stasio, E | 1 |
| Vescini, F | 1 |
| Campagna, G | 1 |
| Cianni, R | 1 |
| Pasqualini, V | 1 |
| Romitelli, F | 1 |
| Grimaldi, F | 1 |
| Manfrini, S | 1 |
| Palermo, A | 1 |
| Walker, J | 1 |
| Farag, N | 1 |
| Delbanco, T | 1 |
| Strewler, GJ | 1 |
| Faggiano, A | 1 |
| Di Somma, C | 1 |
| Ramundo, V | 1 |
| Severino, R | 1 |
| Vuolo, L | 1 |
| Coppola, A | 1 |
| Panico, F | 1 |
| Savastano, S | 1 |
| Lombardi, G | 1 |
| Colao, A | 1 |
| Gasperi, M | 1 |
| Bollerslev, J | 1 |
| Marcocci, C | 1 |
| Sosa, M | 1 |
| Nordenström, J | 1 |
| Bouillon, R | 1 |
| Mosekilde, L | 1 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
| Sandoval, MA | 1 |
| Paz-Pacheco, E | 1 |
| Gołkowski, F | 1 |
| Barczyński, M | 1 |
| Buziak-Bereza, M | 1 |
| Huszno, B | 1 |
| Cichoń, S | 1 |
| Sugimoto, T | 1 |
5 reviews available for alendronate and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Alendronate; Calcium; Cinacalcet; Denosumab; Estrogens; Humans; Hyperparathyroidism, Primary; Parath | 2022 |
Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Deno | 2023 |
Primary hyperparathyroidism and the role of the nurse.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Humans; Hyperca | 2016 |
Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism.
Topics: Alendronate; Animals; Bone Resorption; Evidence-Based Medicine; Humans; Hypercalcemia; Hyperparathyr | 2011 |
[Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Calcium; Diagnosis, Differential; Diagnos | 2007 |
2 trials available for alendronate and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Humans; Hyperpar | 2013 |
Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cholecal | 2015 |
8 other studies available for alendronate and Hyperparathyroidism, Primary
| Article | Year |
|---|---|
Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate.
Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Case-Control St | 2013 |
Osteoprotegerin serum levels in primary hyperparathyroidism and changes following surgery.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism, | 2014 |
Osteoprotegerin in primary hyperparathyroidism.
Topics: Alendronate; Bone Density Conservation Agents; Bone Remodeling; Female; Humans; Hyperparathyroidism, | 2014 |
Update: A 64-year-old woman with primary hyperparathyroidism.
Topics: Adenoma; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Progressio | 2008 |
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Cinac | 2011 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |
Primary hyperparathyroidism with classic and severe skeletal involvement.
Topics: Adenoma; Alendronate; Calcitriol; Calcium Carbonate; Female; Follow-Up Studies; Fractures, Spontaneo | 2010 |
[New horizons for increased sensitivity of radionuclide imaging in primary hyperparathyroidism].
Topics: Adenoma; Adult; Alendronate; Female; Humans; Hyperparathyroidism, Primary; Image Enhancement; Middle | 2006 |